Point72 (DIFC)’s BioAtla BCAB Stock Holding History

Point72 (DIFC)’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1	Closed	-$19	–	1672
2024 Q4	$19	Hold	1	–	–	﹤0.01%	1466
2024 Q3	$84	Sell	1 -344	-100%	-$28.8K	﹤0.01%	1369
2024 Q2	$23.6K	Buy	+345	New	+$41K	﹤0.01%	1205

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Point72 (DIFC)'s BCAB Position: Q1 2025 in Review

Point72 (DIFC) sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 1 share — an estimated $19 sold.

Point72 (DIFC) first reported a position in BCAB in Q2 2024 and held it in 3 quarters. The position peaked at $23.6K in Q2 2024. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

Point72 (DIFC) reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 1 BioAtla share in Q1 2025, an estimated $19.
Point72 (DIFC) first reported a position in BioAtla in Q2 2024 and held it in 3 quarters.
Point72 (DIFC)'s BioAtla position peaked at $23.6K in Q2 2024.
41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.